Characterization of salvicine-resistant lung adenocarcinoma A549/SAL cell line
Open Access
- 15 March 2004
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 110 (5), 627-632
- https://doi.org/10.1002/ijc.20026
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Cytotoxicity, apoptosis induction and downregulation of MDR‐1 expression by the anti‐topoisomerase II agent, salvicine, in multidrug‐resistant tumor cellsInternational Journal of Cancer, 2003
- Drug discovery and p53Drug Discovery Today, 2003
- Death and anti-death: tumour resistance to apoptosisNature Reviews Cancer, 2002
- ApoptosisCell, 2002
- Multidrug resistance in cancer: role of ATP–dependent transportersNature Reviews Cancer, 2002
- Salvicine, a novel DNA topoisomerase II inhibitor, exerting its effects by trapping enzyme-DNA cleavage complexes 1 1Abbreviations: ADM, adriamycin; VP16, etoposide; Topo, topoisomerase; kDNA, knetoplast DNA; HCPT, hydrocamptothecin; SC, supercoiled form; RLX, relaxed form; LNR, linear form; and NC, nicked form.Biochemical Pharmacology, 2001
- Differential Gene Expression in the Activation and Maturation of Human MonocytesArchives of Biochemistry and Biophysics, 2000
- The MDM2 Oncoprotein Promotes Apoptosis in p53-Deficient Human Medullary Thyroid Carcinoma Cells1Endocrinology, 2000
- Disruption of p53 in human cancer cells alters the responses to therapeutic agentsJCI Insight, 1999
- Decreased Mutation Rate for Cellular Resistance to Doxorubicin and Suppression of mdrl Gene Activation by the Cyclosporin PSC 833JNCI Journal of the National Cancer Institute, 1995